**Product:** Birinapant

**ALTERNATE NAME:** (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[[2R,4S]-4-hydroxy-1-[(2S)-2-[(2S)-2-[(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl][methyl]-1H-indol-2-yl]-1H-indol-3-yl][methyl]-4-hydroxy-pyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide; TL32711; SMAC mimetic

**CATALOG #:** 2597-1, 5

**AMOUNT:** 1 mg, 5 mg

**STRUCTURE:**

![Structure Image]

**MOLECULAR FORMULA:** C_{42}H_{56}F_{2}N_{8}O_{6}

**MOLECULAR WEIGHT:** 806.94

**CAS No.:** 1260251-31-7

**APPEARANCE:** White to off-white solid

**SOLUBILITY:** DMSO (>50 mg/ml)

**PURITY:** >98% by HPLC

**STORAGE:** Store at -20°C. Protect from air and light

**DESCRIPTION:** Birinapant is a SMAC (synthetic small molecule and peptidomimetic of second mitochondrial-derived activator of caspases) mimetic and IAP (Inhibitor of Apoptosis Protein) antagonist with potential antineoplastic activity. Birinapant binds to and inhibits the activity of IAPs, such as X chromosome-linked IAP (XIAP) and cellular IAPs 1 and 2. Since IAPs shield cancer cells from the apoptosis process, this agent may restore and promote the induction of apoptosis through apoptotic signaling pathways in cancer cells.


**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**
- Actinomycin D (Cat. No. 1036-50, 50MG, 5MG)
- Anisomycin (Cat. No. 1549-10)
- BAM7 (Cat. No. 2451-5, 25)
- Berberine chloride (Cat.No. 1830-100, 500)
- Brefeldin A (Cat. No. 1560-5, 50)
- Camptothecin (Cat. No. 1039-1, 100, 50MG, 500MG)
- Carboplatin (Cat. No. 1553-100)
- Colchicine (Cat.No.1519-1000)
- Cycloheximide (Cat. No. 1041-1, 1G)
- Cyclosporine A (Cat. No. 1522-100)
- Daunorubicin HCI (Cat. No. 1524-10, 50, 500)
- Dexamethasone (Cat. No. 1042-1, 1G, 10G)
- Doxorubicin HCI (Cat. No. 1527-5)
- Etoposide (Cat. No. 1043-100, 25Mg, 250MG)
- LY573636 (Cat. No. 2297-5, 25)
- Ready-to-Use Apoptosis Inducer Set (Cat. No. K121-5)

**FOR RESEARCH USE ONLY! Not to be used in humans.**